Literature DB >> 28314227

Reliability and validity of Chinese version of perceived deficits questionnaire for depression in patients with MDD.

Chuan Shi1, Gang Wang2, Feng Tian3, Xiaolei Han3, Sha Sha2, Xiaomeng Xing2, Xin Yu4.   

Abstract

Although cognitive symptoms are prevalent and negatively affect psychosocial functioning, they are not commonly assessed in clinical practice, particularly in China. Perceived Deficits Questionnaire for Depression (PDQ-D) provides a subjective measure of cognitive dysfunction. This study aimed to examine the psychometric properties of Chinese version of PDQ-D in patients with MDD. The study sample comprised of 129 patients with MDD and 128 community volunteers. All patients with MDD were assessed with PDQ-D, Sheehan Disability Scale (SDS), Work Productivity and Activity Impairment: Specific Health Problem (WPAI-SPH), Patient Health Questionnaire-9 item (PHQ-9), and Digit Symbol Substitution Test (DSST). Community volunteers were assessed with PDQ-D, PHQ-9 and DSST. The Chinese version of PDQ-D showed excellent internal consistency and test-retest reliability. Three factors were identified and together explained 62.48% of the total variance. Validity of the PDQ-D was supported by its significant correlations with self-reported impaired work productivity, disability in all sub-domains of SDS, along with significant difference between community volunteers and MDD patients in PDQ-D. The questionnaire also significantly correlated with PHQ-9, but no correlation between PDQ-D and DSST was found. The Chinese version of the PDQ-D was found to be psychometrically valid to evaluate subjective cognitive dysfunction in patients with MDD.
Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cognition; Depression; Perceived deficits questionnaire for depression in patients with MDD (PDQ-D); Reliability; Validity

Mesh:

Year:  2017        PMID: 28314227     DOI: 10.1016/j.psychres.2017.03.021

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  6 in total

1.  Reliability and Validity of THINC-it in Evaluating Cognitive Function of Patients with Bipolar Depression.

Authors:  Weihua Zhang; Na Zhu; Jianbo Lai; Jingjing Liu; Chee H Ng; Jun Chen; Chao Qian; Yanli Du; Chanchan Hu; Jingkai Chen; Jianbo Hu; Zhong Wang; Hetong Zhou; Yi Xu; Yiru Fang; Chuan Shi; Shaohua Hu
Journal:  Neuropsychiatr Dis Treat       Date:  2020-10-21       Impact factor: 2.570

2.  Psychometric validation of the Perceived Deficits Questionnaire-Depression (PDQ-D) instrument in US and UK respondents with major depressive disorder.

Authors:  Raymond W Lam; François-Xavier Lamy; Natalya Danchenko; Aaron Yarlas; Michelle K White; Benoît Rive; Delphine Saragoussi
Journal:  Neuropsychiatr Dis Treat       Date:  2018-10-29       Impact factor: 2.570

3.  Vortioxetine Modulates the Regional Signal in First-Episode Drug-Free Major Depressive Disorder at Rest.

Authors:  Shihong Xiong; Wei Li; Yang Zhou; Hongwei Ren; Guorong Lin; Sheng Zhang; Xi Xiang
Journal:  Front Psychiatry       Date:  2022-06-29       Impact factor: 5.435

4.  Impact of Cognitive Symptoms on Health-Related Quality of Life and Work Productivity in Chinese Patients with Major Depressive Disorder: Results from the PROACT Study.

Authors:  Gang Wang; Kristin Hui Xian Tan; Hongye Ren; Lene Hammer-Helmich
Journal:  Neuropsychiatr Dis Treat       Date:  2020-03-13       Impact factor: 2.570

5.  Prevalence and association of depression with uremia in dialysis population: a retrospective cohort analysis.

Authors:  Jin Liu; Fan Zhang; Yujie Wang; Dan Wu
Journal:  Medicine (Baltimore)       Date:  2020-06-12       Impact factor: 1.817

Review 6.  Assessing cognition in people with severe mental disorders in low- and middle-income countries: a systematic review of assessment measures.

Authors:  Yohannes Gebreegziabhere Haile; Kassahun Habatmu; Andualem Derese; Hetta Gouse; Stephen M Lawrie; Matteo Cella; Atalay Alem
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2021-06-18       Impact factor: 4.328

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.